We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Simple Cervical Cancer Exams Proposed for Low-Resource Settings

By Labmedica staff writers
Posted on 12 Mar 2008
Cervical cancer, caused by the human papillomavirus (HPV), affects about 500,000 women each year and kills 270,000 worldwide annually. More...
There is a huge discrepancy between cervical cancer deaths in rich and poor nations--80-85% of deaths occur in the developing world. In developed countries, screening programs using the Pap smear are in place to spot disease and treat it early. However, a successful Pap testing program requires a high degree of organization, sophisticated laboratory equipment, and highly trained technicians. In spite of government efforts, large-scale Pap screening programs have failed in poorer regions.

During a panel presentation at the Goethe-Institut (Washington, DC, USA) on March 5, 2008, Dr. Jacqueline Sherris of PATH (formally: Program for Appropriate Technology in Health), an Alliance for Cervical Cancer Prevention (ACCP) founder, noted, "cervical cancer represents a huge global inequity with a heavy burden on poor women.”

A painless visual screening method has been found to be as effective, if not more effective, as the Pap smear. For the visual screening method, a trained health worker swabs the patient's cervix with vinegar. After one minute, any small lesions on the cervix--signs of potential future cancer--can be seen with the naked eye.

"In most cases it is possible to treat women for precancer during the same visit to the clinic,” said Dr. Harshad Sanghvi of the Johns Hopkins Program for International Education in Gynecology and Obstetrics (JHPIEGO; Baltimore, MD, USA), an ACCP partner. "This is important because if a woman is sent home the day of the exam and asked to come back days or weeks later to hear the results and be treated, she may not be able to return. In the past, many women have missed the care they needed for this reason. Treatment in the late stages of cervical cancer--when women suffer symptoms--is difficult and often not successful. We need to screen all women, beginning at age 30, and provide rapid treatment to those who need it,” Dr. Sanghvi added.

Dr. R. Sankaranarayanan, from the International Agency for Research on Cancer (IARC; Lyons, France), has studied alternatives to Pap smear screening in India and other countries. He explained that cervical cancer is easy to treat if precancerous signs are detected early. Treatment in low-resource settings often can be implemented using a device that destroys the affected tissue by freezing, the same way that common warts are frozen.

"New technologies for cervical cancer prevention are revolutionizing public health,” stated Silvana Luciani of the Pan American Health Organization (PAHO; Washington, DC, USA). "Visual screening methods, high-tech DNA tests for HPV, and the new HPV vaccines represent incredible opportunities to strengthen prevention. We need to protect girls from HPV infection with vaccine, but immunization is not a substitute for screening.

Screening programs are needed to care for women who may have already been infected with HPV, because the vaccine does not protect them effectively and there are cancer-causing types of HPV not targeted by the vaccine. Research indicates that a combination of vaccination and screening can dramatically reduce cervical cancer deaths in the coming decades.”


Related Links:
Goethe-Institut
Johns Hopkins Program for International Education in Gynecology and Obstetrics
International Agency for Research on Cancer

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Gastrointestinal Panel
Xpert® GI Panel
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: MPNST is a cancer of the connective tissue surrounding peripheral nerves, with NF1 being a key risk factor (Image Credit: Nephron/Wikimedia Commons (CC BY-SA 3.0)

Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors

Malignant peripheral nerve sheath tumor (MPNST) is one of the most serious cancers affecting people with neurofibromatosis type 1 (NF1), yet timely recognition remains difficult. Clinicians often struggle... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Type 1 diabetes affects more than 9 million people worldwide and can begin years before symptoms appear, making early identification of at-risk children difficult (Image Credit: iStock)

Early-Life Gut Microbiome Changes May Help Assess Type 1 Diabetes Risk

Type 1 diabetes (T1D) affects more than 9 million people worldwide, including 1.8 million children and adolescents, and often begins years before symptoms appear. Early identification of children who are... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.